Actively Recruiting
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Led by GlaxoSmithKline · Updated on 2026-04-23
150
Participants Needed
43
Research Sites
140 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Asthma is a chronic condition marked by narrowed and swollen airways due to inflammation leading to recurring symptoms that can vary and worsen unpredictably.\\xa0The purpose of this study is to assess how depemokimab, a monoclonal antibody, affects the structure and function of the lungs in asthmatic participants with type 2 inflammation, characterized by an eosinophilic phenotype.
CONDITIONS
Official Title
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Documented diagnosis of asthma for 2 years or more
- Eosinophilic phenotype with blood eosinophils ≥300 cells/mcL at screening or in past 3 months
- Exhaled nitric oxide (FeNO) ≥25 ppb at screening
- History of 2 or more exacerbations needing systemic corticosteroids in past 12 months despite medium to high dose inhaled corticosteroids
- Uncontrolled asthma with ACQ-5 score >1.5 at screening
- Pre-bronchodilator FEV1 less than 80% predicted at screening
- Regular treatment with medium or high dose inhaled corticosteroids for past 12 months with or without oral corticosteroids
- Current use of at least one additional asthma controller medication besides inhaled corticosteroids for 3 months or more
- Female participants must not be pregnant or breastfeeding and must use highly effective contraception if of childbearing potential
- Negative pregnancy test within 24 hours before first dose for females of childbearing potential
- Able to provide written informed consent
- For bronchoscopy sub-study: no maintenance oral corticosteroids at screening, post-bronchodilator FEV1 ≥50% predicted, no bleeding risks or contraindications to bronchoscopy, no allergies to anesthesia
You will not qualify if you...
- Known lung conditions other than asthma such as bronchiectasis, pulmonary fibrosis, aspergillosis, lung cancer, emphysema, or chronic bronchitis
- Other causes of high eosinophils like eosinophilic granulomatosis with polyangiitis or eosinophilic esophagitis
- Asthma exacerbation within 4 weeks before screening
- Parasitic infections within 6 months unless treated and resolved
- Known immunodeficiency except due to corticosteroid use for asthma
- Current cancer or cancer remission less than 12 months
- Significant uncontrolled cardiac, endocrine, autoimmune, metabolic, neurological, psychiatric, renal, gastrointestinal, hepatic, or blood disorders
- Diagnosis of vasculitis
- Prior failure with anti-IL-5/5R therapy
- Recent monoclonal antibody treatment targeting IL-5/5R, IL-4R/IL-13, IL-33, IgE, or TSLP within 12 months
- Investigational drug use within 30 days before first dose
- Participation in biologic asthma treatment studies within 12 months
- History of alcohol or substance misuse within 2 years
- Current smokers, former smokers with 20 or more pack years, and vapers
- Allergy or intolerance to monoclonal antibodies or depemokimab ingredients
- Pregnant or breastfeeding
- Known poor adherence to asthma controller medications
- High ionizing radiation exposure or recent multiple CT scans in certain body areas
- Presence of metal objects interfering with chest CT
- Significant abnormal lab results at screening as judged by investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 43 locations
1
GSK Investigational Site
Brooksville, Florida, United States, 34613
Actively Recruiting
2
GSK Investigational Site
Plantation, Florida, United States, 33324
Actively Recruiting
3
GSK Investigational Site
Kansas City, Kansas, United States, 66160
Actively Recruiting
4
GSK Investigational Site
St Louis, Missouri, United States, 63110
Actively Recruiting
5
GSK Investigational Site
New Brunswick, New Jersey, United States, 08901
Actively Recruiting
6
GSK Investigational Site
New York, New York, United States, 10029
Actively Recruiting
7
GSK Investigational Site
DuBois, Pennsylvania, United States, 15801
Actively Recruiting
8
GSK Investigational Site
Philadelphia, Pennsylvania, United States, 19140-5103
Actively Recruiting
9
GSK Investigational Site
McKinney, Texas, United States, 75069
Actively Recruiting
10
GSK Investigational Site
Mechelen, Belgium, 2800
Actively Recruiting
11
GSK Investigational Site
Namur, Belgium, 5101
Actively Recruiting
12
GSK Investigational Site
Ajax, Ontario, Canada, L1S 2J5
Actively Recruiting
13
GSK Investigational Site
Hamilton, Ontario, Canada, L8N 3Z5
Actively Recruiting
14
GSK Investigational Site
London, Ontario, Canada, N6A 5A5
Actively Recruiting
15
GSK Investigational Site
Guangzhou, China, 510163
Actively Recruiting
16
GSK Investigational Site
Shanghai, China, 200080
Actively Recruiting
17
GSK Investigational Site
Tianjin, China, 300052
Actively Recruiting
18
GSK Investigational Site
Brest, France, 29200
Actively Recruiting
19
GSK Investigational Site
Créteil, France, 94010
Actively Recruiting
20
GSK Investigational Site
La Tronche, France, 38700
Actively Recruiting
21
GSK Investigational Site
Pessac, France, 33604
Actively Recruiting
22
GSK Investigational Site
Reims, France, 51092
Actively Recruiting
23
GSK Investigational Site
Bonn, Germany, 53127
Actively Recruiting
24
GSK Investigational Site
Frankfurt, Germany, 60389
Actively Recruiting
25
GSK Investigational Site
Athens, Greece, 106 76
Actively Recruiting
26
GSK Investigational Site
Athens, Greece, 115 21
Actively Recruiting
27
GSK Investigational Site
Heraklion, Greece
Actively Recruiting
28
GSK Investigational Site
Ioannina, Greece, 45500
Actively Recruiting
29
GSK Investigational Site
Thessaloniki, Greece
Actively Recruiting
30
GSK Investigational Site
Roma, Italy, 00168
Actively Recruiting
31
GSK Investigational Site
Barcelona, Spain
Actively Recruiting
32
GSK Investigational Site
Barcelona, Spain
Actively Recruiting
33
GSK Investigational Site
Benalmádena, Spain, 29631
Actively Recruiting
34
GSK Investigational Site
Madrid, Spain, 28031
Actively Recruiting
35
GSK Investigational Site
Palma de Mallorca, Spain, 070120
Actively Recruiting
36
GSK Investigational Site
Santander, Spain, 39008
Actively Recruiting
37
GSK Investigational Site
Kaohsiung City, Taiwan
Actively Recruiting
38
GSK Investigational Site
Taichung, Taiwan, 407
Actively Recruiting
39
GSK Investigational Site
Taipei, Taiwan, 100
Actively Recruiting
40
GSK Investigational Site
Bradford, United Kingdom, BD9 6RJ
Actively Recruiting
41
GSK Investigational Site
London, United Kingdom, SE1 9RT
Actively Recruiting
42
GSK Investigational Site
London, United Kingdom, W6 8RF
Actively Recruiting
43
GSK Investigational Site
Southampton, United Kingdom, SO16 6YD
Actively Recruiting
Research Team
U
US GSK Clinical Trials Call Center
CONTACT
E
EU GSK Clinical Trials Call Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here